Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp173 | Obesity (1) | ECE2019

Excellent tumor response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma

Coopmans Eva , van Meyel Sebastiaan , Pieterman Kay , van Ipenburg Jolique , Hofland Leo , Donga Esther , Daly Adrian , Beckers Albert , van der Lely Aart-Jan , Neggers Sebastian

Background: Prolactinomas are the most frequent secreting pituitary adenomas encountered in the clinical setting. Cabergoline is considered the mainstay medical treatment and transsphenoidal surgery (TSS) is recommended for patients that are medically resistant to dopamine agonist therapy. Resistance to dopamine agonists is commonly defined as failure to normalize prolactin and less than 50% decrease in tumor diameter at a maximal labeled dose of 2.0 mg/week. Pasireotide LAR (...